Drugs / sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02911870 | Sep 2016 → May 2017 | — | Novo Nordisk A/S | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium N-(8-[2-hydroxybenzoyl] amino) caprylate | “with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC, 300 mg).” PMID 34319564 ↗ Jul 2021 |
| Known as | SNAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02911870 ↗ |
| Route | Oral | “escalating single oral doses of SNAC” PMID 34319564 ↗ Jul 2021 |